$9.46
-2.2%eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
EXOZ • NASDAQ
| eXoZymes, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||
-9.2M | -5.9M | -2M | -1.4M | -1.2M | |
-52.9K | 267.4K | 196.9K | 147.8K | 59.4K | |
2M | 1.1M | 281.5K | 216.5K | 198.5K | |
341.3K | -19.4K | 158.7K | -35.2K | -99K | |
(0.0) | (0.0) | (63.6K) | (0.0) | (0.0) | |
380.2K | -4M | 220.3K | -190.1K | -536.5K | |
-6.5M | -8.5M | -1.2M | -1.3M | -1.6M | |
INVESTING ACTIVITIES | |||||
-169.9K | -396.5K | -288.7K | -186K | -422.6K | |
19.7K | 37.2K | -22.5K | 98.8K | 110.3K | |
-150.2K | -359.2K | -311.2K | -87.2K | -312.3K | |
FINANCING ACTIVITIES | |||||
0.0 | 14.5M | 0.0 | 1.4M | 2.3M | |
-27.7K | 4M | 0.0 | 0.0 | 0.0 | |
0.0 | 11.8K | 1M | 0.0 | 0.0 | |
-27.7K | 18.5M | 1M | 1.4M | 2.3M | |
CASH FLOW SUMMARY | |||||
-6.7M | 9.7M | -492K | 10.8K | 413.4K | |
9.7M | 66.5K | 558.6K | 547.8K | 134.4K | |
3M | 9.7M | 66.5K | 558.6K | 547.8K | |
-6.7M | -8.9M | -1.5M | -1.4M | -2M |
EXOZ - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | January 29, 2026 | 2026 | |
S-3 S-3 N/A | January 16, 2026 | January 16, 2026 | ||
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your EXOZ research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.